Pharmafile Logo
Pharmafocus logo
Advanced Search

Wickham Laboratories Announces New In Vitro Pyrogenicity Testing Method

July 6, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Wickham Laboratories is pleased to announce the introduction of a new in vitro test method, the Monocyte Activation Test, for …

News
Press release
az_logo

AstraZeneca trigger $10 million milestone payment for Heptares in immuno-oncology candidate

July 6, 2016
Research and Development, Sales and Marketing AstraZeneca, Heptares

AstraZeneca (LSE: AZN) is set to deliver a payment of $10 million to Heptares Therapeutics after the first patient was …

News

Sanofi says to co-develop Zika vaccine with US government

July 6, 2016
Research and Development, Sales and Marketing Sanofi, US government, Vaccine, Zika virus, drug development, research

French drugmaker Sanofi (Euronext: SAN) said it will co-develop a Zika vaccine candidate with the US government.  No financial details …

News

Bristol-Myers Squibb acquires Cormorant Pharmaceuticals in deal worth up to $425 million

July 6, 2016
Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, cormorant

Bristol-Myers Squibb (NYSE: BMY) has announced that it has acquired all outstanding capital stock of Sweden-based Cormorant Pharmaceuticals, granting it …

News

Sanofi signs confidentiality agreement with Medivation for due diligence access for potential deal

July 6, 2016
Research and Development, Sales and Marketing Financial, M&A, MA, Medivation, Sanofi, deal, offer

Sanofi (Euronext: SAN) confirmed it has entered a confidentiality agreement with cancer drugmaker Medivation (Nasdaq: MDVN) under which it will …

News

Nice rejects BMS’ immunotherapy Opdivo for previously treated kidney cancer on pricing

July 5, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Bristol-Myers Squibb, NICE, QALY, immunotherapy, opdivo, regulation

UK regulators have rejected Bristol-Myers Squibb’s (NYSE: BMY) immunotherapy Opdivo for previously treated kidney cancer on pricing and substantial uncertainty …

News

UCB scores Japanese approval for seizure therapy, Vimpat

July 5, 2016
Manufacturing and Production, Research and Development Daiichi Sankyo, Japan, UCB, japanese

UCB Biopharma (EURONEXT: UCB) and Daiichi Sankyo have announced that Vimpat (lacosamide) has been approved as an adjunctive therapy in …

News

Sanofi, Regeneron say cholesterol drug Praluent approved in Japan

July 5, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Japan, Regeneron, Sanofi, cardiovascular, cholestrol, praleunt

Sanofi (Euronext: SAN) and Regeneron Pharmaceuticals (Nasdaq: REGN) said the lawmakers in Japan have granted marketing and manufacturing authorization for …

News
eisa0005

Eisai launches cancer drug Lenvatinib in Mexico

July 4, 2016
Research and Development, Sales and Marketing Cancer, Eisai, Mexico, lenvatinib, product launch

Japanese drug firm Eisai Co (TYO: 4523) said it has launched its anticancer agent Lenvima (lenvatinib mesylate) in Mexico. Lenvima …

News
allergan

Allergan says its double chin correction therapy Belkyra gets positive opinion from Swedish regulators

July 4, 2016
Research and Development, Sales and Marketing Allergan, Belkyra, Botox, EU, Sweden, double chin, drug trial

Botox maker Allergan (NYSE: AGN) said it has received a positive opinion from the Swedish Medical Products Agency for its …

News
amgen_hq

Amgen says its blood cancer drug gets European backing for extended indication

July 4, 2016
Research and Development, Sales and Marketing Amgen, European Commission, Kyprolis, blood cancer, drug trial

Amgen (Nasdaq: AMGN) said the European Commission (EC) has approved a variation to the marketing authorization for its Kyprolis (carfilzomib) to include use …

News
mr058666-web

Merck says its Erbitux in combination with Folfox improves outcomes in colorectal cancer

July 4, 2016
Research and Development, Sales and Marketing Cancer, China, ESMO, Merck, colorectal cancer, drug trial, research, study

Merck said late-stage trials for its Erbitux (cetuximab) in combination with Folfox significantly improved progression free survival in metastatic colorectal …

News
stocks1

Weekly Movers: Regulus, Nymox, Akers…

July 4, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Shares, drug trial, markets, stocks

Shares in Regulus Therapeutics (Nasdaq: RGLS) dropped after the company said it has received verbal notification from the US Food …

Feature
astrazeneca_building_white

AstraZeneca licenses skin-condition drug to Leo Pharma for $115 million upfront

July 1, 2016
Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Deals, Licencing, Loe Pharna, Valeant, drug development

UK drug firm AstraZeneca (LSE: AZN) said it has licenced its drug for skin diseases to Leo Pharma for an …

News

US doctors received $6.5 billion from drug, device firms in 2015

July 1, 2016
Medical Communications, Research and Development, Sales and Marketing US, affordable care act, pharma, regulation

Doctors and hospitals received nearly $6.5 billion in research and speaking fees as well as other goods or services from …

News
abpilogo1

UK healthcare professionals received £340.3 million in benefits from pharma industry in 2015 discloses ABPI

July 1, 2016
Business Services, Medical Communications, Sales and Marketing ABPI, Pharmacutical, corruption, disclosure, regulation

“We don’t want our neighbours to know what we earn,” said Mike Thompson, the chief executive of industry body Association …

News
abbvie_0

AbbVie’s Imbruvica secures fourth breakthrough therapy designation from US FDA

July 1, 2016
Medical Communications, Research and Development, Sales and Marketing AbbVie, US FDA, drug trial, imbruvica

US pharma firm AbbVie (NYSE: ABBV) said the US Food and Drug Administration has granted Imbruvica a fourth breakthrough therapy …

News
shire_image

Shire says Phase II trial for rare eye condition in premature infants fails

July 1, 2016
Medical Communications, Research and Development Shire, US FDA, drug trial, rare eye condition in infants

Shire plc (LSE: SHP) said its drug compound to treat a rare eye condition in infants failed mid-stage trials. The …

News
bayercross3

Bayer says its Stivarga improved overall survival in liver cancer in late-stage trials

June 30, 2016
Research and Development, Sales and Marketing Bayer, Stivarga, drug trial, liver cancer

German pharma and crop sciences giant Bayer (ETR: BAYN) said late-stage trials for its drug to treat liver cancer showed a …

News
stocks

Galena’s breast cancer immunotherapy fails in late-stage trials; shares plunge

June 30, 2016
Research and Development, Sales and Marketing Galena Biopharma, Stock, breast cancer, drug trial

Shares in Galena Biopharma (Nasdaq: GALE) dropped over 80% after the company said an independent Data Monitoring Committee recommended that …

News
The Gateway to Local Adoption Series

Latest content

Kayentis and RWS partner to improve clinical trial data confidence

April 17, 2026

MHRA expands its pioneering AI Airlock programme with £3.6m funding boost

April 16, 2026

Ardena opens new US bioanalytical laboratory

April 15, 2026

Gesynta Pharma doses first patient in endometriosis phase 2 trial

April 14, 2026

Astellas Pharma’s new non-hormonal menopausal hot flush treatment Veoza can be used in the NHS, NICE says

April 13, 2026